Hypertension, a leading cause of global mortality, necessitates effective management to mitigate cardiovascular and renal disease risks. Monotherapy often proves inadequate, with approximately 75% of hypertensive patients requiring combination treatment. Preferred combinations include angiotensin-receptor blockers and calcium channel blockers, with some patients needing triple combination therapy. Recently introduced fixed-dose tablet formulations, such as Azusa T, Uniaz T, Telma-AZ, and Zeblong T, combine Azelnidipine and Telmisartan for hypertension treatment. Two validated UV spectrophotometric methods, utilizing simultaneous equation and absorbance ratio techniques, have been developed for the simultaneous estimation of Azelnidipine and Telmisartan in pure powder and two-component dosage forms. The methods measure absorbance at 252 nm and 296 nm, and the iso-absorptive wavelength of 268 nm in methanol. Azelnidipine and Telmisartan obeyed Beer's law at their respective λmax, demonstrating linearity in the concentration ranges of 1.6-8 µg/mL and 4-20 µg/mL, with correlation coefficients of 0.9998 for both. Statistical validation adhered to ICH guidelines, confirming the methods' reliability for routine analysis of Azelnidipine and Telmisartan in pharmaceutical formulations.